1. Gregor A, Rampling R, Aapro M, Malmstrom P, Whittle IR, Rye R, Stewart M, Sellar R, Demierre B, Ironside JW, Wahlby S, Smyth JF: Phase II study of tauromustine in malignant glioma. Eur J Cancer 28A(12): 1959?1962, 1992
2. Macdonald DR, Cascino TL, Schold SC, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7): 1277?1280, 1990
3. Taylor SA, Upchurch C, Goodwin W, Brown T, Selby G, Vogel FS, Eyre H: Assessment of response to new agents for primary CNS malignancies. Proc Am Soc Clin Oncol 12: 502, 1993 (abstr/poster)
4. Taylor S, Belt RG, Joseph U, Haas CD, Hoogstraten B: Phase I evaluation of AT-125 single dose every three weeks. IND 2: 311?314, 1984
5. McGovern JD, Stewart JC, Elfring GL, Smith RB, Soares N, Wood JH, Poplack DG, Von Hoff DD: Plasma and cerebrospinal fluid pharmacokinetics of acivicin in Ommaya reservoir-bearing Rhesus monkeys. Cancer Treat Rep 65: 1333?1341, 1982